Patient - PACT
New Clinical Trial and Research

Trial title	A PHASE 2, MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF ENV-101 (TALADEGIB) IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
Trial synopsis	This research study aims to look at how safe the study drug, ENV-101, is and how well it is tolerated in patients with IPF. The study will also look at the effects ENV-101 has on how patients feel, lung function, and overall quality of life. ENV-101 tablets are taken orally daily. Participants taking part in the study will have a 50-50 chance of receiving either the study medication or a placebo. A placebo is a medication with no active ingredients. It looks like the ENV-101 tablets but does not contain the study medication. This study has three main periods: the screening period (2 weeks), the treatment period (12 weeks) and the follow-up period (6 weeks).
Investigational medicinal product	Subjects will receive either 200 mg of taladegib (ENV-101) or placebo.
Disease target	Mild to Moderate Idiopathic pulmonary fibrosis (IPF)
Sponsor	Endeavor Biomedicines, Inc.
Duration	20 weeks
Trial Status	Recruiting
Lead site(s) in Australia	N/A
Lead site(s) in New Zealand	N/A
Additional sites	AUSTRALIA • VIC Monash Medical Centre Clayton, Xun Li • VIC Box Hill Hospital, Frank Thien • NSW Liverpool Hospital, Zinta Harrington • QLD Pindara Private Hospital, Iain Feather
Contact	pactcoordinator@cre-pf.org.au